Palynziq
Pre-clinicalRecruiting 0 watching 0 views this week💤 Quiet
20
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Phenylketonurias
Conditions
Phenylketonurias
Trial Timeline
Oct 8, 2019 → Dec 1, 2028
NCT ID
NCT04404530About Palynziq
Palynziq is a pre-clinical stage product being developed by BioMarin Pharmaceutical for Phenylketonurias. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04404530. Target conditions include Phenylketonurias.
Hype Score Breakdown
Clinical
5
Activity
2
Company
7
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04404530 | Pre-clinical | Recruiting |
Competing Products
7 competing products in Phenylketonurias
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Sapropterin | BioMarin Pharmaceutical | Pre-clinical | 20 |
| Pegvaliase | BioMarin Pharmaceutical | Pre-clinical | 20 |
| sapropterin dihydrochloride | BioMarin Pharmaceutical | Phase 2 | 49 |
| sapropterin dihydrochloride | BioMarin Pharmaceutical | Phase 3 | 74 |
| sapropterin dihydrochloride, 6R-BH4, tetrahydrobiopterin | BioMarin Pharmaceutical | Phase 3 | 74 |
| Pegvaliase-Pqpz | BioMarin Pharmaceutical | Pre-clinical | 20 |
| Sapropterin Dihydrochloride + Placebo | BioMarin Pharmaceutical | Phase 3 | 74 |